The New York Times on Tuesday May 14 contained an op-ed by Angelina Jolie, the actress and director. In it she discloses that she has a family history of breast cancer and that she decided to have a double mastectomy before cancer developed. I have written about this as a patent issue in the past, talking about the Myriad case before the United States Supreme Court, but Ms Jolie’s op-ed puts a personal and familiar face to the problem of genetic issues and patent protection.
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
From seller vetting and proprietary screening technology to brand collaboration and industry partnerships, Temu explains how its intellectual property enforcement programme combats infringement on its marketplace
A handful of US firms have quietly invested in European patent talent. Recent moves by Baker Botts and K&L Gates suggest that trend may be accelerating
Loke Khoon Tan and Stephanie Yip at Dentons explain what brand owners need to know ahead of January 1 2027, when updates to China’s Trade Mark Law come into force
Octavio Espejo of Becerril, Coca & Becerril explains how sweeping patent reforms reshape filing strategies, prosecution, and divisional application practice
PE-backed practices now comprise the majority of ranked firms for patent prosecution in the Netherlands, but competitors are confident about their decision to remain independent
Richard Quatrano, counsel at Olshan Frome Wolosky, shares why technology M&A buyers and sellers must verify written IP assignments, as broken ownership chains can undermine valuation, deal terms, and closing certainty
Appointment of AI and copyright expert Anna Naydonov, as well as another partner from Orrick, shows how firms can attract top litigators through leveraging the power of their existing teams